<DOC>
	<DOCNO>NCT00202280</DOCNO>
	<brief_summary>The purpose study determine whether Vitamin B12 , B6 Folic Acid effective antipsychotic medication treatment First Episode Psychosis.The B-complex Vitamins ' homocysteine lower property may effect cognition symptom . We examine change symptom cognition 3 month period .</brief_summary>
	<brief_title>Efficacy Treating First Episode Psychosis With Folic Acid , B12 B6 Addition Antipsychotic Medication</brief_title>
	<detailed_description>The core rationale study prospectively investigate whether Vitamin B12 , B6 Folic Acid associate lower homocysteine level improve /or protect cognitive functioning cohort 120 first episode psychosis patient . This randomized , double blind placebo control add standard therapy trial vitamin B12 , B6 folic acid , young patient 15-25 present ORYGEN Youth Health first psychotic episode . Vitamins ( B12 , B6 Folate ) compare placebo added standard treatment period 12 week double blind fashion . Primary outcome measure psychopathology cognition ( CogState MATRICS ) . Secondary outcome measure tolerability safety measure ( drop-out rate , general side effect scale ( UKU ) . Patients give informed consent randomise receive treatment vitamin ( 5 mg folic acid , 0.4 mg B12 , 50 mg B6 ) daily placebo 12 week . Patients randomise dynamic randomisation method call minimization allocate patient treatment group check allocation similar patient already randomise , allocate next treatment group `` live '' best balance treatment group across stratification variable . The minimization carry NHMRC clinical trial centre Sydney , patient randomize either placebo vitamin . Each patient collect tablet clinical trial pharmacy . The Clinical Trials Pharmacy dispense either vitamin placebo . All study personnel participant blind treatment assignment duration study . To enhance quality measurement ( increase power study avoid dilution effect ) adherence medication measure electronically electronic pill cap ( Medication Event Monitoring System VI , ARRDEX Ltd ) . This allow u assess actual pharmacological exposure objective manner .</detailed_description>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Male female Between 15 25 year age First Episode Psychosis 3 month treatment Attending ORYGEN Youth Health , geographical base catchment area service young people age 15 25 Untreated B12 deficiency untreated pernicious anaemia Patients multivitamin , single B6 , folic acid , unless willing discontinue take study supplement Chronic haemolytic state thalassaemia major sicklecell anaemia Hypersensitivity folic acid Organic disorder present psychotic syndrome ( e.g . brain tumour , temporal lobe epilepsy , HIV encephalopathy ) Mental retardation ( unable and/or unlikely give appropriate information symptomatology sideeffects ( IQ approximately low 70 ) History clinically significant physical illness ( e.g . terminal cancer , renal dialysis ) History brain surgery History brain infarction Pregnant lactate woman , woman childbearing potential use acceptable method contraception</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>